BMS receives US FDA approval for Camzyos to treat cardiomyopathy
The approval is based on findings from Phase III EXPLORER-HCM clinical trial that enrolled 251 adults with obstructive HCM.
Cardiovascular
Latest in
Cardiovascular
Kyttaro and Lilly sign licence agreement for monoclonal antibody programme
The antibodies showed potential for treating individuals who are at high-risk for atherosclerotic cardiovascular disease.
ACC 22: empagliflozin produces clinical benefits for patients with acute heart failure
The additional clinical benefits empagliflozin offers will strengthen its position in an increasingly competitive SGLT-2I class.
By
ACC 22: mavacamten improves health status in symptomatic hypertrophic cardiomyopathy
Mavacamten is a selective cardiac myosin inhibitor currently in pre-registration for hypertrophic cardiomyopathy (HCM) in the US.
By
EC approves Boehringer-Lilly’s Jardiance for chronic heart failure
The EC approval is based on results from the Phase III EMPEROR-Preserved trial of 10mg empagliflozin versus placebo.
FDA grants approval to Boehringer-Lilly’s Jardiance for heart failure
The approval is based on results from the Phase III EMPEROR-Preserved clinical trial of a once-daily dose of 10mg empagliflozin.
Abbisko Therapeutics and Lilly partner to develop new molecules
Abbisko is eligible to receive up to $258m in milestone payments from Lilly.
BenevolentAI and AstraZeneca expand drug discovery partnership
The companies collaborated initially in 2019 to use AI and machine learning to develop new therapies for CKD and IPF.